أعرض في EDS

The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study

التفاصيل البيبلوغرافية
العنوان: The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study
المؤلفون: Khadhouri, Sinan, Gallagher, Kevin M., MacKenzie, Kenneth R., Shah, Taimur T., Gao, Chuanyu, Moore, Sacha, Zimmermann, Eleanor F., Edison, Eric, Jefferies, Matthew, Nambiar, Arjun, Mannas, Miles P., Lee, Taeweon, Marra, Giancarlo, Lillaz, Beatrice, Gómez Rivas, Juan, Olivier, Jonathan, Assmus, Mark A., Uçar, Taha, Claps, Francesco, Boltri, Matteo, Burnhope, Tara, Nkwam, Nkwam, Tanasescu, George, Boxall, Nicholas E., Downey, Alison P., Lal, Asim A, Antón-Juanilla, Marta, Clarke, Holly, Lau, David H. W., Gillams, Kathryn, Crockett, Matthew, Nielsen, Matthew, Takwoingi, Yemisi, Chuchu, Naomi, O'Rourke, John, MacLennan, Graeme, McGrath, John S., Kasivisvanathan, Veeru, Chaudry, Aasem, Sharma, Abhishek, Bennett, Adam, Ahmad, Adnan, Abroaf, Ahmed, Suliman, Ahmed M, Lloyd, Aimee, McKay, Alastair, Wong, Albert, Silva, Alberto, Schneider, Alexandre, MacKay, Alison, Knight, Allen, Grigorakis, Alkiviadis, Bdesha, Amar, Nagle, Amy, Cebola, Ana, Dhanasekaran, Ananda Kumar, Kond?a, Andra?, Barcelos, André, Galosi, Andrea B, Ebur, Andrea, Minervini, Andrea, Russell, Andrew, Webb, Andrew, García de Jalón, Ángel, Desai, Ankit, Czech, Anna K, Mainwaring, Anna, Adimonye, Anthony, Das, Arighno, Figueiredo, Arnaldo, Villers, Arnauld, Leminski, Artur, Chippagiri, Arvinda, Y?ld?r?m, As?f, Voulgaris, Athanasios M, Uzan, Audrey, Oo, Aye Moh Moh, Younis, Ayman, Zelhof, Bachar, Mukhtar, Bashir, Ayres, Ben, Challacombe, Ben, Sherwood, Benedict, Ristau, Benjamin, Lai, Billy, Nellensteijn, Brechtje, Schreiter, Brielle, Trombetta, Carlo, Dowling, Catherine, Hobbs, Catherine, Benitez, Cayo Augusto Estigarribia, Lebacle, Cédric, Ho, Cherrie Wing Yin, Ng, ChiFai, Mount, Chloe, Lam, Chon Meng, Blick, Chris, Brown, Christian, Gallegos, Christopher, Higgs, Claire, Browne, Clíodhna, McCann, Conor, Alonso, Cristina Plaza, Beder, Daniel, Cohen, Daniel, Gordon, Daniel, Wilby, Daniel, Gordon, Danny, Lau, David Hua Wu, Hrouda, David, Karsza, Dávid, Mak, David, Martin-Way, David, Suthaharan, Denula, Patel, Dhruv, Carrion, Diego M, Nyanhongo, Donald, Bass, Edward, Mains, Edward, Chau, Edwin, Castillo, Elba Canelon, Day, Elizabeth, Desouky, Elsayed, Gaines, Emily, Papworth, Emma, Yuruk, Emrah, Kilic, Enes, Dinneen, Eoin, Palagonia, Erika, Xylinas, Evanguelos, Khawaja, Faizan, Cimarra, Fernando, Bardet, Florian, Kum, Francesca, Peters, Francesca, Kovács, Gábor, Tanasescu, Geroge, Hellawell, Giles, Tasso, Giovanni, Lam, Gitte, La Montagna, Giuseppe, Pizzuto, Giuseppe, Lenart, Gordan, Özgür, Günal, Bi, Hai, Lyons, Hannah, Warren, Hannah, Ahmed, Hashim, Simpson, Helen, Burden, Helena, Gresty, Helena, Pita, Hernado Rios, Serag, Hosam, Kynaston, Howard, Crawford-Smith, Hugh, Mostafid, Hugh, Otaola-Arca, Hugo, Fen Koo, Hui, Ibrahim, Ibrahim, Ouzaid, Idir, Puche-Sanz, Ignacio, Tomakovi, Igor, Tinay, Ilker, Sahibzada, Iqbal, Thangasamy, Isaac, Cadena, Iván Revelo, Irani, Jacques, Udzik, Jakub, Brittain, James, Catto, James, Green, James, Tweedle, James, Hernando, Jamie Borrego, Leask, Jamie, Kalsi, Jas, Frankel, Jason, Toniolo, Jason, Raman, Jay D, Courcier, Jean, Kumaradeevan, Jeevan, Clark, Jennifer, Jones, Jennifer, Teoh, Jeremy YuenChun, Iacovou, John, Kelly, John, Selph, John P, Aning, Jonathan, Deeks, Jon, Maw, Jonny, Herranz-Yagüe, José Antonio, Nolazco, Jose Ignacio, Cózar-Olmo, Jose Manuel, Bagley, Joseph, Jelski, Joseph, Norris, Joseph, Testa, Joseph, Meeks, Joshua, Hernandez, Juan, Vásquez, Juan Luis, Randhawa, Karen, Dhera, Karishma, Gronostaj, Katarzyna, Houlton, Kathleen, Lehman, Kathleen, Adasonla, Kelvin, Brown, Kevin, Murtagh, Kevin, Mistry, Kiki, Davenport, Kim, Kitamura, Kosuke, Derbyshire, Laura, Clarke, Laurence, Morton, Lawrie, Martinez, Levin, Goldsmith, Louise, Paramore, Louise, Cormier, Luc, Dell'Atti, Lucio, Simmons, Lucy, Martinez-Piñeiro, Luis, Rico, Luis, Chan, Luke, Forster, Luke, Ma, Lulin, Moore, Madeline, Gallego, Maria Camacho, Freire, Maria José, Emberton, Mark, Feneley, Mark, Rivero, Marta Viridiana Muñoz, Pira, Matea, Tallè, Matteo, Liew, Matthew, Trail, Matthew, Cooper, Meghan, Kulkarni, Meghana, Ager, Michael, He, Ming, Li, Mo, Omran Breish, Mohamed, Tarin, Mohamed, Aldiwani, Mohammed, Matanhelia, Mudit, Pasha, Muhammad, Akaln, Mustafa Kaan, Abdullah, Nasreen, Hale, Nathan, Gadiyar, Neha, Kocher, Neil, Bullock, Nicholas, Campain, Nicholas, Pavan, Nicola, Al?Ibraheem, Nihad, Bhatt, Nikita, Bedi, Nishant, Shrotri, Nitin, Lobo, Niyati, Balderas, Olga, Kouli, Omar, Capoun, Otakar, Manjavacas, Pablo Oteo, Gontero, Paolo, Mariappan, Paramananthan, Marchiñena, Patricio Garcia, Erotocritou, Paul, Sweeney, Paul, Planelles, Paula, Acher, Peter, Black, Peter C, Osei?Bonsu, Peter K, Østergren, Peter, Smith, Peter, Willemse, Peter-Paul Michiel, Chlosta, Piotr L, Ul Ain, Qurrat, Barratt, Rachel, Esler, Rachel, Khalid, Raihan, Hsu, Ray, Stamirowski, Remigiusz, Mangat, Reshma, Cruz, Ricardo, Ellis, Ricky, Adams, Robert, Hessell, Robert, Oomen, Robert J.A., McConkey, Robert, Ritchie, Robert, Jarimba, Roberto, Chahal, Rohit, Andres, Rosado Mario, Hawkins, Rosalyn, David, Rotimi, Manecksha, Rustom P, Agrawal, Sachin, Hamid, Syed Sami, Deem, Samuel, Goonewardene, Sanchia, Swami, Satchi Kuchibhotla, Hori, Satoshi, Khan, Shahid, Inder, Shakeel Mohammud, Sangaralingam, Shanthi, Marathe, Shekhar, Raveenthiran, Sheliyan, Horie, Shigeo, Sengupta, Shomik, Parson, Sian, Parker, Sidney, Hawlina, Simon, Williams, Simon, Mazzoli, Simone, Kata, Slawomir Grzegorz, Lopes, Sofia Pinheiro, Ramos, Sónia, Rai, Sonpreet, Rintoul-Hoad, Sophie, O'Meara, Sorcha, Morris, Steve, Turner, Stacey, Venturini, Stefano, Almpanis, Stephanos, Joniau, Steven, Jain, Sunjay, Mallett, Susan, Nikles, Sven, Yan, Shahzad Sylvia, Drake, Tamsin, Toma, Tarq, Plo, Teresa Cabañuz, Bonnin, Thierry, Muilwijk, Tim, Wollin, Tim, Chu, Timothy Shun Man, Appanna, Timson, Brophy, Tom, Ellul, Tom, Austin, Tomas, Smrkolj, Toma, Rowe, Tracey, Sukhu, Troy, Patel, Trushar, Garg, Tullika, Çakurlu, Turhan, Bele, Uros, Haroon, Usman, Crespo-Atín, Víctor, Cortes, Victor Parejo, Poves, Victoria Capapé, Gnanapragasam, Vincent, Gauhar, Vineet, During, Vinnie, Kumar, Vivek, Fiala, Vojtech, Mahmalji, Wasim, Lam, Wayne, Chin, Yew Fung, Filtekin, Yigit, Phan, Yih Chyn, Ibrahim, Youssed, Glaser, Zachary A, Adwin, Zainal, Qin, Zijian, Zotter, Zsuzsanna, Zainuddin, Zulkifli
المساهمون: Khadhouri, Sinan, Gallagher, Kevin M, Mackenzie, Kenneth R, Shah, Taimur T, Gao, Chuanyu, Moore, Sacha, Zimmermann, Eleanor F, Edison, Eric, Jefferies, Matthew, Nambiar, Arjun, Mannas, Miles P, Lee, Taeweon, Marra, Giancarlo, Lillaz, Beatrice, Gómez Rivas, Juan, Olivier, Jonathan, Assmus, Mark A, Uçar, Taha, Claps, Francesco, Boltri, Matteo, Burnhope, Tara, Nkwam, Nkwam, Tanasescu, George, Boxall, Nicholas E, Downey, Alison P, Lal, Asim Ahmed, Antón-Juanilla, Marta, Clarke, Holly, Hw Lau, David, Gillams, Kathryn, Crockett, Matthew, Nielsen, Matthew, Takwoingi, Yemisi, Chuchu, Naomi, O'Rourke, John, Maclennan, Graeme, Mcgrath, John S, Kasivisvanathan, Veeru, Khadhouri, Sinan [0000-0002-1836-8992], Moore, Sacha [0000-0002-0914-2051], Gómez Rivas, Juan [0000-0002-0556-3035], Olivier, Jonathan [0000-0002-5409-2911], Assmus, Mark A [0000-0003-3615-9251], Claps, Francesco [0000-0003-2812-5553], Nkwam, Nkwam [0000-0003-1086-6388], Apollo - University of Cambridge Repository
المصدر: Khadhouri, S, Gallagher, K M, MacKenzie, K R, Shah, T T, Gao, C, Moore, S, Zimmermann, E F, Edison, E, Jefferies, M, Nambiar, A, Mannas, M P, Lee, T, Marra, G, Lillaz, B, Gómez Rivas, J, Olivier, J, Assmus, M A, Uçar, T, Claps, F, Boltri, M, Burnhope, T, Nkwam, N, Tanasescu, G, Boxall, N E, Downey, A P, Lal, A A, Antón-Juanilla, M, Clarke, H, Lau, D H W, Gillams, K, Crockett, M, Nielsen, M, Takwoingi, Y, Chuchu, N, O’Rourke, J, MacLennan, G & McGrath, J S & Kasivisvanathan, V 2021, ' The IDENTIFY study : the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer – a multicentre observational study ', BJU International, vol. 128, no. 4, pp. 440-450 . https://doi.org/10.1111/bju.15483Test
سنة النشر: 2021
مصطلحات موضوعية: Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, Male, Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. Patients and Methods This was an international multicentre prospective observational study. We included patients aged >= 16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer, stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. Results Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05, P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15, P < 0.001), male sex 1.30 (95% CI 1.14-1.50, P < 0.001), and smoking 2.70 (95% CI 2.30-3.18, P < 0.001). Conclusions A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer, renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), bladder cancer, cancer prevalence, haematuria, hematuria, prostate cancer, renal cancer, upper tract urothelial cancer, urinary tract cancer, Adult, Aged, Female, Hematuria, Humans, Kidney Neoplasms, Middle Aged, Prospective Studies, Referral and Consultation, Ureteral Neoplasms, Urinary Bladder Neoplasms, Disease, urologic and male genital diseases, Prostate cancer, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, adjusted for established patient risk markers and geographical variation. Patients and Methods This was an international multicentre prospective observational study. We included patients aged >= 16 years, Medicine, bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, education.field_of_study, and smoking 2.70 (95% CI 2.30-3.18, stratified by age, female genital diseases and pregnancy complications, renal cancer and prostate cancer, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer, age 1.04 (95% CI 1.03-1.05 [stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. Results Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were], UTUC (n = 128) 1.14% (95% CI 0.77-1.52), 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), visible haematuria 3.47 (95% CI 2.90-4.15, type of haematuria, P < 0.001), medicine.medical_specialty, Urology, Urinary system, Population, and countries. Results Of the 11 059 patients assessed for eligibility, Malignancy, smoking, UTUC, Internal medicine, sex, education, Bladder cancer, and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05, business.industry, Cancer, Odds ratio, medicine.disease, male sex 1.30 (95% CI 1.14-1.50, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, P < 0.001). Conclusions A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, hospitals, business
الوصف: Funder: Action Bladder Cancer UK
Funder: Rosetrees Trust; Id: http://dx.doi.org/10.13039/501100000833Test
Funder: Urology Care Foundation; Id: http://dx.doi.org/10.13039/100006280Test
OBJECTIVE: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. PATIENTS AND METHODS: This was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. RESULTS: Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15; P < 0.001), male sex 1.30 (95% CI 1.14-1.50; P < 0.001), and smoking 2.70 (95% CI 2.30-3.18; P < 0.001). CONCLUSIONS: A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer.
وصف الملف: ELETTRONICO; application/pdf; text/xml
اللغة: English
تدمد: 1464-4096
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::344e57ee215ddddcac45c0a5efc724dfTest
https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.15483Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....344e57ee215ddddcac45c0a5efc724df
قاعدة البيانات: OpenAIRE
الوصف
تدمد:14644096